The anti-receptor activator of NF-kappaB ligand antibody denosumab treatment was associated with significant increases in serum sclerostin levels in postmenopausal osteoporosis (33); however, others reported serum sclerostin concentrations was not affected by denosumab or zoledronic acid medication (34). This evidence concerns the gene SOST and postmenopausal osteoporosis.